Prime Therapeutics LLC acquires Magellan Rx Management

On May 5, 2022, Prime Therapeutics LLC acquired Magellan Rx Management, a life science company in Arizona, United States, from Centene Corp.

Deal at a glance

AnnouncedMay 5, 2022 TypeDivestiture TargetMagellan Rx Management Buyer Prime Therapeutics LLC Seller Centene Corp. SectorLife Science LocationArizona, United States ValueMembers only

Target company

Magellan Rx Management

Arizona, United States

Life Sciencesector

1992founded

Activestatus

View the company profile →

Buyer

Prime Therapeutics LLC

Company · 1 deal on record

1st transaction in life science
1st transaction in United States

1deals, all time

1in this sector

2022latest

Seller

Centene Corp.

Company · 22 deals on record

22investments

2in this sector

2exits

Members only

Contact details at the buyers and sellers

The full deal history of every party

Co-investors and the other advisors on this deal

Deal value and revenue or EBITDA multiples

Related deals

PANTHERx Rare LLCSame seller · May 2022

Orbus Therapeutics, Inc.Same sector and country · Oct 2026

ArtesRx LLCSame sector and country · Aug 2026

Firefly Bio, Inc.Same sector and country · Jul 2026

Questions about this deal

Who acquired Magellan Rx Management?Prime Therapeutics LLC acquired Magellan Rx Management on May 5, 2022.

Who sold Magellan Rx Management?Centene Corp. was the seller.

What type of deal was it?It was a divestiture in the life science sector in 2022.

See the full picture on AcquityDataContacts, full deal histories, co-investors and deal values. Free for a day with your Google account, no card needed.

Try it free

Data updated daily on AcquityData (Acquity Data).